Peroutka S J
Department of Neurology, Stanford University Medical Center, CA 94305-5235.
Headache. 1990;30 Suppl 2:554-60. doi: 10.1111/j.1526-4610.1990.hed30s2554.x.
The introduction of sumatriptan, a novel abortive antimigraine agent, has generated a significant amount of preclinical and clinical interest during the past few years. At the scientific level, sumatriptan is unique in terms of its selective pharmacological properties. The effects of sumatriptan in various experimental paradigms have led to new insights into the pathophysiology of migraine. At the clinical level, sumatriptan appears to be an effective abortive anti-migraine agent with minimal side effects. Its ability to decrease, rather than exacerbate, the nausea and vomiting of migraine appears to be an important advance in the treatment of migraine.
舒马曲坦作为一种新型的偏头痛终止发作药物,在过去几年引发了大量临床前和临床研究兴趣。从科学层面来看,舒马曲坦在其选择性药理特性方面独具特色。舒马曲坦在各种实验范式中的作用为偏头痛的病理生理学带来了新的见解。在临床层面,舒马曲坦似乎是一种有效的偏头痛终止发作药物,副作用极小。它能够减轻而非加剧偏头痛伴随的恶心和呕吐,这似乎是偏头痛治疗方面的一项重要进展。